DRG Market Assessment 보고서

Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Amyotrophic lateral sclerosis (ALS) is a progressively debilitating disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of…

Tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

Since 2018, four novel calcitonin gene-related peptide (CGRP)-targeting monoclonal antibodies (MAbs)—Novartis / Amgen’s Aimovig, Eli Lilly’s Emgality, Teva’s Ajovy, and Lundbeck’s Vyepti…

Clarivate Epidemiology’s coverage of actinic keratosis (AK) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of acne comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of acne for each country, as well…

Clarivate’s primary market research explores how PCPs / pain specialists in the United States navigate the current treatment of chronic pain, with a focus on chronic back pain and OA pain.

The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the…

A handful of newer disease-modifying therapies (DMTs) for multiple sclerosis (MS)—Novartis’s Mayzent, Bristol Myers Squibb’s Zeposia, Novartis’s Kesimpta, and Janssen’s Ponvory—have…